echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Huahai force 1 billion schizophrenic drugs! Just won the first review of the new dosage form is coming soon

    Huahai force 1 billion schizophrenic drugs! Just won the first review of the new dosage form is coming soon

    • Last Update: 2020-07-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Pharmaceutical Network July 10, CDE official website data show that Huahai Pharmaceuticals' Ali-Yuankou collapse 3 class of generic listing applications were acceptedMinnet data show that Huahai Pharmaceuticals' application for a generic listing of 4 types of alysium tablets was approved in March 2020, becoming the first enterprise to evaluate the product, this declaration of the collapse of the tablet, it can be seen that Huahai has sufficient confidence in the variety of ali-YuanFigure 1: Huahai Pharmaceuticals' Ali-Yuankou collapse report informationSource: CDE official website
    Figure 2: Sales of Alysium (units: 10,000 yuan)Source: Mine net China's public medical institutions terminal competition pattern
    alyfense mainly used for the treatment of schizophrenia In 2019, China's urban publichospitals, county-level public hospitals, urban community centers and township hospitals (referred to as China's public medical institutions) terminal psychostable drug generic name TOP20 ranked fifth, sales rose to 1.15 billion yuan, according to Minet.comFrom the dosage form, the largest proportion of general tablets, more than 63%, the leadingenterprisesfor Otsuka Pharmaceuticals;Table 1: Huahai Pharmaceuticals' alysium-related productdeclarationSource: MED China Drug Review Database 2.0Huahai Pharmaceuticals is a representative pharmaceutical company of API-preparation integration, Minet data show that earlier Huahai Pharmaceuticals already has a listeric fennel api, ordinary tablets were also approved in March 2020 and treated as the same, after the successful approval of the oral tablets, will greatly enhance the competitiveness in the market   Source: CDE official website, Minnet database
    review data as of July 9, 2020, if there are any errors, please indicate
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.